The Treatment Burden of Myopic Choroidal Neovascularization

"All patients underwent one intravitreal injection at baseline (0.5 mg ranibizumab or 2.0 mg aflibercept); additional intravitreal injections were administered over the follow-up period based on the above-mentioned activity signs with a pro-re-nata (PRN) treatment protocol. The patients have been followed on a monthly or bimonthly basis. The number of visits and examinations in the 12-month study period will be collected.~Clinical and imaging data of the baseline examination as well as of the 12-month visit (M12) after the first intravitreal injection."